|
|
|
| Effects of Disodium Cantharidinate and Vitamin B6 Injection on Tumor Markers and Adverse Reactions during SOX Regimen in the Treatment of Breast Cancer |
| GAO Qing-dong, KANG Feng |
| General Surgery Ward 1,Yulin Second Hospital,Yulin Shaanxi 719000 |
|
|
|
|
Abstract 【Objective】 To investigate the effect of disodium cantharidinate and Vitamin B6 injection on tumor markers and adverse reactions in patients with breast cancer treated with SOX chemotherapy. 【Methods】A total of 82 patients with advanced breast cancer were randomly divided into control group and observation group,with 41 cases in each group. The control group was treated with simple SOX chemotherapy,and the observation group was treated with disodium cantharidinate and Vitamin B6 injection on the basis of the control group.Objective response rate (RR),immune function(CD3+,CD4+,CD8+,CD4+/CD8+) and serum tumor markers[carbohydrate antigen 153 (CA-153),carcinoembryonic antigen (CEA),carbohydrate antigen 125 (CA-125)] and changes in the levels of interleukin-17 (IL-17),macrophage migration inhibitory factor (MIF) and tumor necrosis factor-α(TNF-α) were compared between the two groups before and after treatment. The adverse reactions of the two groups were observed. 【Results】The RR of the observation group was 95.12% (39/41),which was significantly higher than that of the control group [80.49% (33/41)](P<0.05). After treatment,the levels of CD3+,CD4+,CD4+/CD8+ in the two groups were higher than those before treatment (P<0.05),and the levels of CD8+ were lower than those before treatment (P<0.05); After treatment,CD3+,CD4+,CD4+/CD8+ in the observation group were higher than those in the control group (P<0.05),and CD8+ was lower than those in the control group (P<0.05). The levels of IL-17,MIF,CA-153,CEA,CA-125 and TNF-α in both groups after treatment were lower than those before treatment (P<0.05); The levels of the above indexes in the observation group were lower than those in the control group after treatment (P<0.05). The total incidence of adverse reactions in the observation group was 29.27% (12/41),and there was no significant difference compared with 31.71% (13/41) in the control group (P>0.05). 【Conclusion】Injection of disodium cantharidinate and vitamin B6 during SOX chemotherapy can improve the curative effect,serum tumor markers and immune function of patients with breast cancer,and the risk of adverse reactions is low,which is worthy of clinical promotion.
|
|
Received: 14 February 2022
|
|
|
|
|
|
[1] COHEN O,LAM G,CHOI M,et al. Does the timing of chemotherapy affect post-mastectomy breast reconstruction complications?[J].Clin Breast Cancer,2017,17(4):307-315.
[2] SIMONE M,MARTA B,PIERLUIGI P.Vitamin B6 and cancer risk: a field synopsis and meta-analysis[J].J Natl Cancer Inst,2017,109(3):1-9.
[3] 周斌,季科,辛灵,等.美国肿瘤联合乳腺癌分期系统(第8版)更新内容介绍及解读[J].中国实用外科杂志,2017,37(1):10-14.
[4] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志,2015,191(9):692-754.
[5] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90.
[6] RUGO H S,KLEIN P,MELIN S A,et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer[J].JAMA,2017,317(6): 606-614.
[7] 周锐,董慧明,黄建康,等. 斑蝥酸钠维生素B6注射液对青年乳腺癌术后化疗的影响[J].安徽医药,2018,22(8):1575-1578.
[8] BING F,ZHOU F,LU W,et al. Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer[J].Biomater Sci,2017,5(8):1522-1525.
[9] 全昌银,邱小萍,张志强,等. 斑蝥酸钠维生素B6治疗晚期乳腺癌的疗效及对生存质量、安全性的影响[J].中国普通外科杂志,2019,28(5):636-640.
[10] 郭晓莺,申国宏,赵滨. 斑蝥酸钠维生素B6注射液对乳腺癌辅助化疗患者血清IL-6、IL-17、TNF-α及MIF表达水平的影响[J].武警医学,2019,30(10):885-889.
[11] 丁权,朱燊,黄涛. GP与SOX化疗方案治疗三阴性乳腺癌晚期患者的临床效果比较[J].实用癌症杂志,2021,36(5):800-802.
[12] 李丽静,臧亚茹,梁君伟,等. 斑蝥酸钠维生素B6注射液的疗效与安全性真实世界研究[J].肿瘤药学,2018,8(5):799-802. |
|
|
|
2022, Vol. 39 
